Claims for Patent: 11,407,735
✉ Email this page to a colleague
Summary for Patent: 11,407,735
Title: | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(- 1H-pyrazol-5-yl)pyridine-3-carboxamide |
Abstract: | The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(- 1H-pyrazol-5 -yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease. |
Inventor(s): | Dodd; Stephanie Kay (Ayer, MA), Grandeury; Arnaud (Helfrantzkirch, FR), Suffert; Emmanuel (Basel, CH), Rousaki; Evgenia (Basel, CH) |
Assignee: | NOVARTIS AG (Basel, CH) |
Application Number: | 16/874,622 |
Patent Claims: |
1. Crystalline form A of asciminib hydrochloride characterized by having an x-ray powder diffraction pattern comprising reflections at 2-Theta angles of
12.6.+-.0.2.degree. , 18.9.+-.0.2.degree. and 20.9.+-.0.2.degree. , when measured at a temperature in the range of from 20 to 25.degree. C. with Cu-Kalpha.sub.1,2 radiation having a wavelength of 0.1541.ANG..
2. The crystalline form according to claim 1 characterized by having an x-ray powder diffraction pattern comprising reflections at 2-Theta angles of 12.6 .+-.0.2.degree. , 17.0 .+-.0.2.degree. , 18.9 .+-.0.2.degree. , 20.9 .+-.0.2.degree. and 32.5 .+-.0.2.degree. , when measured at a temperature in the range of from 20 to 25.degree. C. with Cu-Kalpha.sub.1,2 radiation having a wavelength of 0.1541.ANG.. 3. The crystalline form according to claim 1 characterized by having an x-ray powder diffraction pattern comprising at least three 2 theta values selected from the group consisting of 8.5.degree. .+-.0.2.degree. , 9.5.degree. .+-.0.2.degree. , 11.8.degree. .+-.0.2.degree. , 12.3.degree. .+-.0.2.degree. , 12.6.degree. .+-.0.2.degree. , 13.9.degree. .+-.0.2.degree. , 14.8.degree. .+-.0.2.degree. , 15.9.degree. .+-.0.2.degree. , 16.5.degree. .+-.0.2.degree. , 17.0.degree. .+-.0.2.degree. , 17.6.degree. .+-.0.2.degree. , 18.9.degree. .+-.0.2.degree. , 19.1.degree. .+-.0.2.degree. , 19.8.degree. .+-.0.2.degree. , 20.4.degree. .+-.0.2.degree. , 20.9.degree. .+-.0.2.degree. , 21.2.degree. .+-.0.2.degree. , 22.4.degree. .+-.0.2.degree. , 22.7.degree. .+-.0.2.degree. , 23.9.degree. .+-.0.2.degree. , 24.3.degree. .+-.0.2.degree. , 24.8.degree. .+-.0.2.degree. , 25.0.degree. .+-.0.2.degree. , 25.9.degree. .+-.0.2.degree. , 26.8.degree. .+-.0.2.degree. , 27.0.degree. .+-.0.2.degree. , 28.3.degree. .+-.0.2.degree. , 28.6.degree. .+-.0.2.degree. , 28.9.degree. .+-.0.2.degree. , 29.8.degree. .+-.0.2.degree. , 30.5.degree. .+-.0.2.degree. , 31.3.degree. .+-.0.2.degree. , 31.5.degree. .+-.0.2.degree. , 31.8.degree. .+-.0.2.degree. , 32.1.degree. .+-.0.2.degree. , 32.5.degree. .+-.0.2.degree. , 32.9.degree. .+-.0.2.degree. , 33.6.degree. .+-.0.2.degree. , 34.0.degree. .+-.0.2.degree. , 34.6.degree. .+-.0.2.degree. , 35.0.degree. .+-.0.2.degree. , 35.6.degree. .+-.0.2.degree. , 36.3.degree. .+-.0.2.degree. and 38.8.degree. .+-.0.2.degree. , when measured at a temperature in the range of from 20 to 25.degree. C. with Cu -Kalpha.sub.1,2 radiation having a wavelength of 0.1541.ANG.. 4. The crystalline form according to claim 1 characterized by having a differential scanning calorimetry curve comprising an endothermic peak having an onset temperature of 90.degree. C., when measured at a heating rate of 2.degree. C/min. 5. The crystalline form according to claim 1 characterized by having a thermogravimetric analysis curve showing a mass loss of not more than 3.3 weight % based on the weight of the crystalline form, when heated from 30 to 300.degree. C. at a rate of 20.degree. C/min. 6. The crystalline form according to claim 1 characterized by having an x-ray powder diffraction pattern comprising at least four 2 theta values selected from the group consisting of 8.5.degree. .+-.0.2.degree. , 9.5.degree. .+-.0.2.degree. , 11.8.degree. .+-.0.2.degree. , 12.3.degree. .+-.0.2.degree. , 12.6.degree. .+-.0.2.degree. , 13.9.degree. .+-.0.2.degree. , 14.8.degree. .+-.0.2.degree. , 15.9.degree. .+-.0.2.degree. , 16.5.degree. .+-.0.2.degree. , 17.0.degree. .+-.0.2.degree. , 17.6.degree. .+-.0.2.degree. , 18.9.degree. .+-.0.2.degree. , 19.1.degree. .+-.0.2.degree. , 19.8.degree. .+-.0.2.degree. , 20.4.degree. .+-.0.2.degree. , 20.9.degree. .+-.0.2.degree. , 21.2.degree. .+-.0.2.degree. , 22.4.degree. .+-.0.2.degree. , 22.7.degree. .+-.0.2.degree. , 23.9.degree. .+-.0.2.degree. , 24.3.degree. .+-.0.2.degree. , 24.8.degree. .+-.0.2.degree. , 25.0.degree. .+-.0.2.degree. , 25.9.degree. .+-.0.2.degree. , 26.8.degree. .+-.0.2.degree. , 27.0.degree. .+-.0.2.degree. , 28.3.degree. .+-.0.2.degree. , 28.6.degree. .+-.0.2.degree. , 28.9.degree. .+-.0.2.degree. , 29.8.degree. .+-.0.2.degree. , 30.5.degree. .+-.0.2.degree. , 31.3.degree. .+-.0.2.degree. , 31.5.degree. .+-.0.2.degree. , 31.8.degree. .+-.0.2.degree. , 32.1.degree. .+-.0.2.degree. , 32.5.degree. .+-.0.2.degree. , 32.9.degree. .+-.0.2.degree. , 33.6.degree. .+-.0.2.degree. , 34.0.degree. .+-.0.2.degree. , 34.6.degree. .+-.0.2.degree. , 35.0.degree. .+-.0.2.degree. , 35.6.degree. .+-.0.2.degree. , 36.3.degree. .+-.0.2.degree. and 38.8.degree. .+-.0.2.degree. , when measured at a temperature in the range of from 20 to 25.degree. C. with Cu -Kalpha.sub.1,2 radiation having a wavelength of 0.1541.ANG.. 7. The crystalline form according to claim 1 characterized by having an x-ray powder diffraction pattern comprising at least five 2 theta values selected from the group consisting of 8.5.degree. .+-.0.2.degree. , 9.5.degree. .+-.0.2.degree. , 11.8.degree. .+-.0.2.degree. , 12.3.degree. .+-.0.2.degree. , 12.6.degree. .+-.0.2.degree. , 13.9.degree. .+-.0.2.degree. , 14.8.degree. .+-.0.2.degree. , 15.9.degree. .+-.0.2.degree. , 16.5.degree. .+-.0.2.degree. , 17.0.degree. .+-.0.2.degree. , 17.6.degree. .+-.0.2.degree. , 18.9.degree. .+-.0.2.degree. , 19.1.degree. .+-.0.2.degree. , 19.8.degree. .+-.0.2.degree. , 20.4.degree. .+-.0.2.degree. , 20.9.degree. .+-.0.2.degree. , 21.2.degree. .+-.0.2.degree. , 22.4.degree. .+-.0.2.degree. , 22.7.degree. .+-.0.2.degree. , 23.9.degree. .+-.0.2.degree. , 24.3.degree. .+-.0.2.degree. , 24.8.degree. .+-.0.2.degree. , 25.0.degree. .+-.0.2.degree. , 25.9.degree. .+-.0.2.degree. , 26.8.degree. .+-.0.2.degree. , 27.0.degree. .+-.0.2.degree. , 28.3.degree. .+-.0.2.degree. , 28.6.degree. .+-.0.2.degree. , 28.9.degree. .+-.0.2.degree. , 29.8.degree. .+-.0.2.degree. , 30.5.degree. .+-.0.2.degree. , 31.3.degree. .+-.0.2.degree. , 31.5.degree. .+-.0.2.degree. , 31.8.degree. .+-.0.2.degree. , 32.1.degree. .+-.0.2.degree. , 32.5.degree. .+-.0.2.degree. , 32.9.degree. .+-.0.2.degree. , 33.6.degree. .+-.0.2.degree. , 34.0.degree. .+-.0.2.degree. , 34.6.degree. .+-.0.2.degree. , 35.0.degree. .+-.0.2.degree. , 35.6.degree. .+-.0.2.degree. , 36.3.degree. .+-.0.2.degree. and 38.8.degree. .+-.0.2.degree. , when measured at a temperature in the range of from 20 to 25.degree. C. with Cu -Kalpha.sub.1,2 radiation having a wavelength of 0.1541.ANG.. 8. The crystalline form according to claim 1 characterized by having an x-ray powder diffraction pattern similar to FIG. 8. 9. Crystalline form A of asciminib hydrochloride characterized by the following unit cell parameters from x-ray diffraction data measured at 100K: TABLE-US-00011 Space symmetry Triclinic Space group P1 Cell Volume (.ANG..sup.3) 1053.6(6) Crystal Density (g/cm.sup.3) 1 a (.ANG.) 8.203(3) b (.ANG.) 11.116(3) c (.ANG.) 12.627(4) beta (.degree.) 97.711(12) Z 2. 10. Crystalline form A of asciminib hydrochloride characterized by the following unit cell parameters from x-ray diffraction data measured at 298K: TABLE-US-00012 Space symmetry Triclinic Space group P1 Cell Volume (.ANG..sup.3) 1082.9(6) Crystal Density (g/cm.sup.3) 1.491 a (.ANG.) 8.245(3) b (.ANG.) 11.352(4) c (.ANG.) 12.697(4) beta (.degree.) 97.289(18) Z 2. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.